Insider Trading July 7, 2026 07:42 PM

Olesen Value Fund L.P. Disposes of $358,117 in Solitron Devices Holdings Amid Recent Momentum

The 10% stakeholder executed multiple share sales between July 1 and July 7, 2026, as SODI shares climb 67% over the past year.

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
SODI

Olesen Value Fund L.P., a major shareholder in Solitron Devices Inc. (NASDAQ:SODI), has liquidated a portion of its position, reporting sales totaling approximately $358,117. The transactions took place over a six-day window in early July 2026, coinciding with a period of significant price appreciation for the stock. The filing highlights the fund's active management of its holdings as the company's valuation metrics suggest the stock is trading above its calculated fair value.

Olesen Value Fund L.P. Disposes of $358,117 in Solitron Devices Holdings Amid Recent Momentum
SODI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Olesen Value Fund L.P. sold 13,488 shares of SODI between July 1 and July 7, 2026, totaling $358,117.
  • The stock has surged 67% over the past year and 42% in the last six months, trading above its Fair Value.
  • Olesen Value Fund L.P. remains a 10% owner of Solitron Devices, retaining 226,298 shares after the sales.

Olesen Value Fund L.P., recognized as a significant shareholder in Solitron Devices Inc. (NASDAQ:SODI), has executed a series of sales involving the company's common stock. The reported transactions amount to approximately $358,117 in total value. These divestments were not a single event but occurred across multiple dates between July 1 and July 7, 2026. The execution prices for these shares varied slightly, ranging from a low of $26.24 to a high of $26.83 per share.

The timing of these sales is notable given the recent performance trajectory of SODI shares. Over the past twelve months, the stock has experienced a substantial surge of 67%. As of the latest reporting, the shares are trading at $26.79. This recent momentum is further highlighted by a 42% increase in share price over the last six months alone, according to analysis from InvestingPro. The data suggests that the stock is currently trading above its calculated Fair Value, a metric that may have influenced the decision to capitalize on the current market momentum.

The total volume of shares sold by the fund amounts to 13,488 shares. The specific transaction dates and corresponding prices were as follows: on July 1, shares were sold at $26.24; on July 2, the price was $26.40; on July 6, the sale occurred at $26.80; and on July 7, the final reported sale was at $26.83. These figures illustrate a gradual price progression during the liquidation period.

Olesen Value Fund L.P. maintains a substantial position in Solitron Devices, holding a 10% ownership stake. The regulatory filing indicates that these transactions were jointly reported by Olesen Value Fund L.P., Olesen Value Fund GP LLC, Olesen Capital Management LLC, and Christian Olesen. The filing includes a standard disclaimer where these reporting persons disclaim beneficial ownership of the reported shares, except to the extent of their pecuniary interest. While Olesen Value Fund L.P. directly owns the shares, Olesen Value Fund GP LLC, Olesen Capital Management LLC, and Christian Olesen may be considered indirect beneficial owners due to their respective roles within the fund structure.

Following the completion of these sales, the reporting persons collectively retain a holding of 226,298 shares of Solitron Devices common stock. This remaining stake continues to represent a significant interest in the company's equity.

Risks

  • The stock is trading above its Fair Value, suggesting potential overvaluation relative to fundamental models.
  • Rapid price appreciation may lead to volatility, impacting short-term trading dynamics for the stock.

More from Insider Trading

CrowdStrike CEO George Kurtz Executes $3.98 Million Stock Sale Under Pre-Arranged Plan Jul 7, 2026 Palantir CTO Sankar Shyam Executes $24 Million Share Disposition Amid Strategic Expansion Jul 7, 2026 Kymera Therapeutics CEO Mainolfi Executes $5.95M Stock Sale Under Pre-Arranged Plan Jul 7, 2026 Damora Therapeutics Executive Offloads Shares Following RSU Vesting Jul 7, 2026 Circle8 Group Chairman and CEO Franke Divests Shares in Automated Transaction Jul 7, 2026